Assessing Platelet to Lymphocyte and Neutrophil to Lymphocyte Ratios as Indicators of Mucosal Activity in Ulcerative Colitis: A Study at a Teritiary Care Hospital in Tamil Nadu

Arshiya Mubin S.P

Final Year DM Resident, Department of Medical Gastroenterology, Coimbatore Medical College and Hospital, Coimbatore, Tamil Nadu, India

Abstract: *Background: Economical and readily available biomarkers for assessing Ulcerative colitis are need of the hour, for this purpose we evaluated platelet to lymphocyte ratio and neutrophil to lymphocyte ratio in patients with ulcerative colitis. Methods: We analyzed 48 patients with UC who underwent measurement of fecal calprotectin (FC) and endoscopy and 96 matched healthy controls. NLR and PLR were compared between the patients and healthy controls. The endoscopic activity was divided into 2 groups: group 1 (mild to moderate inflammation) and group 2 (severe inflammation) according to the Mayo endoscopic score in UC. Results: To diagnose UC, the optimal cutoff of NLR and PLR was 2.26(sensitivity 54.2%; specificity 90.6%) and 179.8 (sensitivity 35.4%; specificity 90.6%) respectively. The optimal cut off to differentiate group 1 and group 2 was 3.44, 175.9, and 453 μg/g for NLR, PLR, and FC, respectively (sensitivity, 63.6% vs. 90.9% vs. 81.8%; specificity, 81.1% vs. 78.4% vs. 73.0%; positive likelihood ratio, 3.364 vs. 4.205 vs. 3.027; AUC, 0.714 vs. 0.897 vs. 0.813). PLR had the highest AUC and positive likelihood ratio. Conclusion: NLR and PLR are useful in patients with UC from healthy controls. NLR, PLR, and FC may reflect intestinal mucosal conditions.*

Keywords: ulcerative colitis, platelet to lymphocyte ratio, neutrophil to lymphocyte ratio

1. Introduction

Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) that diffusely involves various parts of the colon (1, 2). The disease may be limited to the rectum, or it may involve the entire colon. The main complaints of the patients are bloody diarrhea and abdominal pain (3). Mucosal examination via colonoscopy is the basic method in diagnosis; it monitors the activity of the disease and is used in the follow-up of patients (4).The exacerbations of UC may appear in varying frequency and severity. Bleeding, abdominal pain, and fever are frequent during exacerbations (5).Exacerbation is mild in most patients, and 15% of the patients need hospitalization (6). Colonoscopy is performed after excluding infectious causes, and determining the disease severity is beneficial and guides the clinician for treatment and prognosis of the disease. Ulcers, exudates, fragile mucosa, and bleeding are frequent in cases of active disease (7). Early diagnosis and appropriate treatment of disease exacerbation is important in the course of the disease. Some indirect methods have been recently used to determine the disease activity, and their sensitivity has been studied. The neutrophil-to-lymphocyte ratio (NLR) is one of them (8).Inflammatory markers, including leukocyte count, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) have been well known to increase in case of active diseases. However, the data on the sensitivity of some inflammation markers, including NLR and platelet-to-lymphocyte ratio (PLR) on identifying endoscopic active disease, and their correlation with mucosal injury are scarce. In this study, we investigated the sensitivity of new inflammation markers, NLR and PLR, as well as conventional inflammation markers to determine endoscopically active disease, and their correlation with mucosal injury. In addition, we investigated the sensitivity of NLR and PLR combination to predict disease severity according to mucosal disease.

2. Methods

2.1 Study Design and Subjects

48 patients with UC were analyzed against 96 healthy controls who took colonoscopy and laboratory tests between January 2022 and January 2023 at the Coimbatore Medical College and hospital, Coimbatore, Tamil Nadu.

The healthy controls included people who had undergone check-up at our hospital and had normal colonoscopy findings. Patients were matched based on age and sex to the healthy controls in a 1:2 ratio during the study period. Patients with UC were classified according to the Montreal classification (9).The exclusion criteria included previous bowel resection, indeterminate colitis, infection, neoplastic disorders, hematologic disease, heart or pulmonary disease, autoimmune disease, hepatosplenic disease, and renal insufficiency. The patient's age, sex, disease duration, medical and operation history, disease and endoscopic activity score, classification, laboratory findings, and disease treatment were recorded. This study was approved by the Institutional ethical and research Board of our hospital. The informed consent was obtained.

Figure 1: Flow chart of the study subjects. UC, ulcerative colitis

2.2 Laboratory Values

NLR and PLR were calculated by dividing the absolute neutrophil count by the absolute lymphocyte count and dividing the absolute platelet count by the absolute lymphocyte count, respectively. In healthy controls, the findings of the blood test on the day of the endoscopy were used. In patients with UC, blood and FC tests performed within 1 month and of the endoscopy within 3 months were used. The time between the laboratory tests and endoscopy was 2 days and the interval between FC measurement and endoscopy was 4.5 days.

2.3 Assessment of Clinical and Endoscopic Activities

The UC disease activity was evaluated using the Mayo score. The endoscopic activity was assessed using the Mayo endoscopic subscore. Mayo endoscopic subscore grades were as follows–
Grade 0: Normal or inactive,
Grade 1: Mild,
Grade 2: Moderate,
Grade 3: Severe (10).

In pan-colitis or left-sided colitis, endoscopic activity was scored based on the most inflamed segment of the colon. The patients were divided into 2 groups based on the severity of the degree of inflammation (group 1: no, mild, and moderate inflammation vs. group 2: severe inflammation) to evaluate the usefulness of NLR, PLR, and FC as biomarkers of disease activity in UC. The primary endpoint was the ability of NLR, PLR, and FC to serve as biomarkers of mucosal severity in UC.

3. Statistical Analysis

Student t-test was used to compare continuous data between patients with UC and healthy controls. The Mann-Whitney U test was used to analyze the continuous variables. The receiver operating characteristic (ROC) curve analysis was performed to assess the performance of each biomarker for differentiating mucosal severity in UC. The sensitivity, specificity, and cutoff values were assessed using the ROC curve. A P-value < 0.05 was considered to be statistically significant. The De-Long test was performed to compare the measures and the P-value was adjusted by Bonferroni correction. All statistical analyses were performed using SPSS version 21.0 (SPSS Inc., Chicago, IL, USA) and R version 3.6.1 ('pRoc' and 'OptimalCutpoints' packages; R Foundation for Statistical Computing, Vienna, Austria).

4. Results

4.1 Study Population

144 subjects including 48 patients with UC and 96 healthy controls were reviewed during the study period. The mean age of the patients with UC was 38.9 ± 14.8 years. The male: female ratio was 1.18 (males 26, females 22). The mean Mayo score was 6.8 ± 2.3. The clinical characteristics of the 48 patients with UC are summarized in Table 1.

Table 1: Demographic and Clinical Characteristics of the Study Population

Variable	UC(n=48)
Age at UC diagnosis(yr)	38.9±14.8
Male sex	26(54.2)
Previous operation history	5(10.4)
Appendectomy	1(20.0)
Perianal operation	2(40.0)
Others	2(40.0)
Disease extension at diagnosis at diagnosis	
E1(proctitis)	18(37.5)
E2(left-side dcolitis)	10(20.8)
E3(pan-colitis)	20(41.7)
Disease activity at diagnosis	
Clinical remission (Mayo score 0-2)	1(2.1)
Mild activity (Mayo score 3-5)	17(35.4)
Moderate activity (Mayo score 6-10)	28(58.3)
Severe activity (Mayo score 11-12)	2(4.2)
Disease activity at NLR, PLR and FC measurement	
Clinical remission (Mayo score 0-2)	9(18.8)
Mild activity (Mayo score 3-5)	19(39.6)
Moderate activity (Mayo score 6-10)	15(31.2)
Severe activity (Mayo score 11-12)	5(10.4)
Medication use at NLR, PLR and FC measurement	
5-ASA	33(68.7)
5-ASA+AZA	5(10.4)
5-ASA+steroid	4(8.3)
5-ASA+steroid+AZA	2(4.2)
5-ASA+AZA+anti-TNF	2(4.2)
5-ASA+anti-TNF	2(4.2)

Values are presented as mean ± standard deviation or number (%).
[a]Others: hysterectomy, transurethral resection of bladder.
UC, ulcerative colitis; NLR, neutrophiltolymphocyte ratio; PLR, platelet to lymphocyte ratio; FC, fecal cal protectin; 5-ASA, 5-aminosalicylic acid; AZA, azathioprine; TNF, tumornecrosis factor

4.2 Comparisons of Serum Biomarkers between Patients with UC and Healthy Controls

WBC, NLR, PLR, ESR, and CRP level was significantly higher in patients with UC versus healthy controls. NLR (3.24 ± 2.78 vs. 1.52 ± 0.61) and PLR (187.01 ± 136.94 vs. 132.88 ± 45.72) were considerably elevated in patients with UC versus healthy controls (Table 2). In patients with UC, ESR (43.45 ± 29.96 mm/hr vs. 18.85 ± 15.81 mm/hr) and CRP (0.79 ± 1.43 mg/dL vs. 0.14 ± 0.31 mg/dL) were higher than the upper limit of the reference range (Table 2).

Table 2: Comparisons of Serum Biomarkers between Patients with UC and Healthy Controls

Variable	UC group (n=48)	Control group (n=96)	P-value	Reference
WBC(/µL)	7, 750.00±2, 932.21	5, 335.42±1, 271.46	<0.001	4, 000–10, 000
NLR	3.24±2.78	1.52±0.61	<0.001	-
PLR	187.01±136.94	132.88±45.72	<0.001	-
ESR(mm/hr)	43.45±29.96	18.85±15.81	<0.001	0–30
CRP(mg/dL)	0.79±1.43	0.14±0.31	<0.001	0.0–0.5

Values are presented as mean ± standard deviation.
UC, ulcerative colitis; WBC, white blood cell; NLR, neutrophiltolymphocyte ratio; PLR, platelet tolymphocyte ratio; ESR, erythrocytese dimentation rate; CRP, C-reactive protein.

4.3 Comparisons of Serum Biomarkers between Mild to Moderate UC and Severe UC

NLR, PLR, ESR, CRP, and FC were significantly higher in patients with severe UC (group 2) versus mild to moderate UC (group 1). PLR was higher in group 2 versus group 1 (280.04 ± 106.44 vs. 159.35 ± 133.81, P< 0.001). NLR also was higher in group 2 versus group 1 (4.04 ± 2.25 vs. 3.00 ± 2.91, P= 0.034). FC was significantly increased in group 2 versus group 1 (2, 476.09 ± 2, 572.13 µg/g vs. 575.04 ± 1, 181.98 µg/g, P= 0.002) (Table 3).

Table 3: Comparisons of Serum Biomarkers according to Endoscopic Severity in UC Patients

| Variable	Group1(n = 37) (mild to moderate)	Group 2 (n = 11) (severe)	*P*-value	Reference
WBC (/µL)	7, 635.14 ± 2, 917.88	8, 136.36 ± 3, 089.75	0.508	4, 000–10, 000
NLR	3.00 ± 2.91	4.04 ± 2.25	0.034	-
PLR	159.35 ± 133.81	280.04 ± 106.44	<0.001	-
ESR (mm/hr)	37.75 ± 29.06	62.09 ± 25.99	0.007	0–30
CRP (mg/dL)	0.45 ± 0.97	1.90 ± 2.09	<0.001	0.0–0.5
FC (µg/g)	575.04 ± 1, 181.98	2, 476.09 ± 2, 572.13	0.002	0–100

Values are presented as mean ± standard deviation.
UC, ulcerative colitis; WBC, white blood cell; NLR, neutrophiltolymphocyte ratio; PLR, platelettolymphocyte ratio; ESR, erythrocyte sedimentation rate; CRP, C- reactive protein; FC, fecal calprotectin.

4.4 Comparison of the Diagnostic Accuracy for Predicting UC Using NLR and PLR

ROC analysis was performed to determine the cutoff of NLR and PLR to predict UC. To differentiate patients with UC from healthy controls, WBC had the highest area under the curve (AUC) among NLR, PLR, ESR, and CRP. However, it had the lowest positive likelihood ratio as compared with the other parameters (sensitivity 72.9%; specificity 74.0%; positive likelihood ratio 2.800, 95% confidence interval [CI], 1.917–4.089; AUC 0.793, 95% CI 0.713–0.874). ROC analysis revealed a sensitivity of 54.2% and specificity of 90.6% when an NLR cutoff of 2.26 was used (positive likelihood ratio 5.778, 95% CI 2.944–11.339; AUC 0.774, 95% CI 0.690–0.859). For identifying UC, the optimal cutoff of 179.8 for PLR had a sensitivity of 35.4% and a specificity of 90.6% (positive likelihood ratio 3.778, 95% CI 1.821–7.838; AUC 0.654, 95% CI 0.556–0.753) (Table 4, Fig. 2A). NLR had a significantly higher AUC versus PLR (P= 0.006) before Bonferroni correction, but the difference was no longer statistically significant after correction (Tables 4, 5).

Figure 2: ROC curve showing the diagnostic performance of NLR, PLR, and FC. (A) In the ROC curve, the optimal cut off value for NLR and PLR for detecting UC was 2.26 (sensitivity 54.2%; specificity 90.6%; AUC0.774, 95% CI0.690–0.859) and 179.8 (sensitivity 35.4%; specificity 90.6%, AUC0.654, 95% CI0.556–0.753). (B) The optimal cutoff value for NLR, PLR, and FC for differentiating UC

severity were 3.44 (sensitivity 63.6%; specificity 81.1%; AUC0.714, 95% CI0.539–0.888), 175.9 (sensitivity 90.9%; specificity 78.4%; AUC 0.897, 95%CI, 0.802– 0.992), and 453μg/g (sensitivity 81.8%; specificity 73.0%; AUC 0.813, 95% CI, 0.655–0.972), respectively. ROC, receiver operator characteristic; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; FC, fecal calprotectin; UC, ulcerative colitis; AUC, area under the curve; CI, confidence interval; WBC, white blood cell; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein.

4.5 Comparison of the Diagnostic Accuracy for Severe Endoscopic UC Using NLR, PLR, and FC

The optimal cutoff for differentiating group 1 and 2 patients with UC was 3.44 (sensitivity 63.6%; specificity 81.1%; positive likelihood ratio 3.364, 95% CI 1.507–7.507; AUC 0.714, 95% CI 0.539–0.888) for NLR, 175.9 (sensitivity 90.9%; specificity 78.4%; positive likelihood ratio 4.205, 95% CI 2.214–7.894; AUC 0.897, 95% CI 0.802–0.992) for PLR, and 453 μg/g (sensitivity 81.8%; specificity 73.0%; positive likelihood ratio 3.027, 95% CI 1.664–5.507; AUC 0.813, 95% CI 0.655–0.972) for FC (Table 4, Fig. 2B). PLR had the highest AUC among NLR, PLR, ESR, CRP, and FC and it had a higher positive likelihood ratio than NLR and FC. The AUC for PLR was significantly higher than NLR (P= 0.017) before Bonferroni correction but the difference was no longer statistically significant after the correction (Tables 4, 5).

Table 4: Comparison of the Diagnostic Accuracy for Detecting UC and for Severe Endoscopic UC Using Biomarkers

Parameter	WBC (/μL)			NLR			PLR			ESR (mm/hr)			CRP (mg/dL)			FC (μg/g)		
	Estimate	Lower	Upper	Estimate	Lower	Upper	Estimate	Lower	Upper	Estimate	Lower	Upper	Estimate	Lower	Upper	Estimate	Lower	Upper
Control vs. UC																-	-	-
Cutoff	6,000			2.26			179.8			34			0.2					
Sensitivity	0.729	0.582	0.847	0.542	0.392	0.686	0.354	0.222	0.505	0.617	0.464	0.755	0.574	0.422	0.717			
Specificity	0.740	0.640	0.824	0.906	0.829	0.956	0.906	0.829	0.956	0.865	0.780	0.926	0.833	0.744	0.902			
Positive predictive value	0.583	0.467	0.743	0.743	0.592	0.842	0.654	0.487	0.779	0.690	0.553	0.810	0.628	0.495	0.760			
Negative predictive value	0.845	0.738	0.900	0.798	0.683	0.899	0.737	0.593	0.864	0.822	0.712	0.900	0.800	0.684	0.880			
Positive likelihood ratio	2.800	1.917	4.089	5.778	2.944	11.339	3.778	1.821	7.838	4.556	2.620	7.924	3.447	2.069	5.743			
Negative likelihood ratio	0.366	0.227	0.591	0.506	0.369	0.692	0.713	0.572	0.887	0.443	0.306	0.642	0.511	0.362	0.720			
AUC	0.793	0.713	0.874	0.774	0.690	0.859	0.654	0.556	0.753	0.767	0.677	0.856	0.696	0.596	0.796			
Mild to moderate vs. severe																		
Cutoff	7,300			3.44			175.9			41			0.8			453		
Sensitivity	0.636	0.308	0.81	0.636	0.308	0.891	0.909	0.587	0.998	0.909	0.587	0.998	0.727	0.390	0.940	0.818	0.482	0.977
Specificity	0.649	0.475	0.798	0.811	0.648	0.920	0.784	0.618	0.902	0.667	0.490	0.814	0.861	0.705	0.953	0.730	0.559	0.862
Positive predictive value	0.350	0.209	0.751	0.500	0.301	0.823	0.556	0.358	0.982	0.455	0.286	0.973	0.615	0.381	0.904	0.474	0.297	0.895
Negative predictive value	0.857	0.604	0.928	0.882	0.656	0.953	0.967	0.805	0.987	0.960	0.773	0.981	0.912	0.713	0.971	0.931	0.736	0.969
Positive likelihood ratio	1.811	0.969	3.385	3.364	1.507	7.507	4.205	2.214	7.984	2.727	1.657	4.489	5.236	2.150	12.754	3.027	1.664	5.507
Negative likelihood ratio	0.561	0.248	1.269	0.448	0.202	0.995	0.116	0.018	0.757	0.136	0.021	0.896	0.317	0.120	0.839	0.249	0.070	0.886
AUC	0.566	0.339	0.794	0.714	0.539	0.888	0.897	0.802	0.992	0.769	0.623	0.915	0.854	0.741	0.966	0.813	0.655	0.972

UC, ulcerative colitis; WBC, white blood cell; NLR, neutrophilto lymphocyte ratio; PLR, platelet to lymphocyte ratio; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; FC, fecal calprotectin; AUC, area under the curve.

Table 5: Comparisons between Biomarkers on Healthy Control versus UC and Mild to Moderate versus Severe UC

Parameter			Control vs. UC		Mild to moderate vs severe	
			P-value[a]	Adjusted[P]-value[b]	P-value[a]	Adjusted P-value[b]
WBC		PLR	0.69	1	0.037	0.56
		NLR	0.036	0.363	0.005	0.071
		ESR	0.712	1	0.143	1
		CRP	0.131	1	0.046	0.693
		FC	-	-	0.122	1
PLR		NLR	0.006	0.059	0.017	0.165
		ESR	0.962	1	0.68	1
		CRP	0.19	1	0.214	1
		FC	-	-	0.457	1
NLR		ESR	0.061	0.612	0.045	0.449
		CRP	0.511	1	0.49	1
		FC	-	-	0.374	1
ESR		CRP	0.181	1	0.26	1
		FC	-	-	0.714	1
CRP		FC	-	-	0.674	1

[a]*P*-value by De Long test
[b]*P*-value adjusted by Bonferroni correction.
UC, ulcerative colitis; WBC, white blood cell; PLR, platelet tolymphocyte ratio; NLR, neutrophiltolymphocyte ratio; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; FC, fecalcal protectin.

5. Discussion

In this study, we studied the use of NLR, PLR, and FC to diagnose UC and their ability to indicate the disease activity. The results suggest that increased NLR and PLR helped to categorise patients with UC from healthy controls. Also NLR, PLR, and FC indicated endoscopic activity. To the best of our knowledge, though previous studies have compared NLR and PLR with clinical indices, no study has fully investigated the connection between NLR, PLR, and FC with endoscopic activity in UC.

Mucosal healing, indicated by the absence of ulcerations and erosions, is assessed by endoscopy and is the treatment aim in UC as it may prevent relapse and complications and to minimize the need for hospitalization or surgery (11-13). Although endoscopy is a irreplaceable tool to identify mucosal inflammation, it is invasive, inconvenient, and may be inappropriate in severe cases as it can cause major complications such as perforation (14).Therefore, non-invasive biomarkers such as WBC, CRP, ESR have been used to identify intestinal inflammation in patients with IBD, albeit with insufficient sensitivity (15, 16).NLR and PLR can diagnose and predict the severity of IBD (17-20). Our study suggests that elevated NLR and PLR help segregate patients with UC from healthy controls. WBC, including neutrophils (that reflect systemic inflammation), contribute to the innate and adaptive immunity and these cells migrate to the inflamed tissues by releasing proinflammatory cytokines and chemokine (21).

An elevated platelet count can contribute to the pathogenesis of mucosal inflammation by its pro-inflammatory properties such as the release and recruitment of inflammatory mediators and modulation of other inflammatory cells (22-24). In contrast, a reduced lymphocyte count in UC may result from mucosal infiltration (25). This results in an elevation of NLR and PLR, which was considerably elevated in patients with UC versus healthy controls in our study. A cutoff of 2.26 for NLR and 179.8 for PLR suggested UC.

NLR was more significant than PLR for diagnosing UC. In previous studies, the optimal cutoff for NLR and PLR was 2.13–3.10 and ~139, respectively which is similar to our results (2.26 for NLR and 179.8 for PLR) (17, 19, 20). The cutoff for PLR was slightly higher than previously reported. The difference in PLR cutoff between our study and the previous study may influence the number of enrolled patients and the use of drugs such as azathioprine, steroids, anti-tumor necrosis factor (anti-TNF) and disease activity.

Our results demonstrated that NLR, PLR, and FC reflect intestinal mucosal conditions in UC. Recently, stool tests such as FC have been suggested as novel biomarkers. FC is a calcium- and zinc-binding protein that comprises 60% of the neutrophil- cytosolic protein (26). A high level of FC in IBD can be due to an increased neutrophil migration into the intestinal mucosa and an increased leukocyte turnover (27). However, FC requires stool sampling (19, 28, 29) and is relatively expensive as compared with NLR and PLR. In this study, PLR had the highest AUC among NLR, PLR, ESR, CRP, and FC. Although there were no significant differences, these results suggest that a high PLR was more meaningful to measure the severity of mucosal inflammation than FC. Interestingly, NLR is a more significant biomarker than PLR to differentiate patients with UC from healthy controls, but PLR was more significant in distinguishing severe UC from mild to moderate UC. This difference could be due to a comparison between different groups. Therefore, our study suggests that NLR and PLR should be considered together when evaluating and treating patients with UC.

This study has several limitations.
1) It was a single-center study with a relatively small sample size.
2) There may be a selection bias as only patients with UC who underwent both endoscopy and FC testing were enrolled. This limits the strength of our conclusions.
3) FC data were not available for controls because this test is not routinely performed. However, NLR and PLR, which were calculated from CBC, can be used routinely

as a noninvasive and low-cost biomarker for identifying UC as per our results.

4) Although CBC (especially absolute neutrophil counts) is affected by drugs such as azathioprine, steroids, and anti-TNF, we did not exclude all patients who took these drugs. However, the difference in neutrophil, lymphocyte, platelet, NLR, and PLR was not statistically significant between the patients on these drugs versus the patients on only 5-aminosalicylic acid. This may be because we included a relatively small number of patients on these medications, and those with an abnormal CBC had previously adjusted the drug dose or changed the medication. Finally, we could not use blood and FC tests performed on the same day as the endoscopy for patients with UC. For more precise comparisons between FC or other biomarkers and endoscopic activity, patients must provide stool and blood samples on the day of endoscopy. However, in clinical practice, these tests are not usually performed on the same day. Therefore, the interval between FC and endoscopy may have contributed to the relatively low correlation between them as compared with previous studies. The results of our study should be interpreted in light of these limitations. To overcome these limitations, prospective studies, including larger cohorts are needed. Despite these limitations, our results suggest that an elevated PLR and NLR instead of FC could be used to indicate endoscopic activity and differentiate patients with UC from healthy controls in real practice.

In conclusion, both NLR and PLR can serve as biomarkers to separate patients with UC from healthy controls. These ratios may also reflect the state of the intestinal mucosa, especially in patients with UC where colonoscopy is not possible.

References

[1] Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the2005 Montreal World Congress of Gastroenterology. Can J Gastro enterol 2005; 19: 5–36.

[2] Singh UP, Singh NP, Murphy EA, Price RL, Fayad HR, Nagarkatti M, et al. Chemokine and cytokine levelsin inflammatory bowel disease patients. Cytokine 2016; 77: 44–9.

[3] Langholz E, Munkholm P, Nielsen OH, Kreiner S, Binder V. Incidence and prevalence of ulcerative colitis in Copenhagen county from 1962 to 1987. Scand J Gastroenterol 1991; 26: 1247–56.

[4] Leighton JA, Shen B, Baron TH, Adler DG, Davila R, Egan JV, et al. Standards of Practice Committee, American Society for Gastrointestinal Endoscopy: endoscopy in the diagnosis and treatment of inflammatory bowel disease. Gastrointest Endosc 2006; 63: 558–65.

[5] Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007; 369: 1641–57.

[6] Farmer RG, Easley KA, Rankin GB. Clinical patterns, natural history, and progression of ulcerative colitis. A long-term follow-up of 1116 patients. Dig Dis Sci 1993; 38: 1137–46.

[7] Bousvaros A, Antonioli DA, Colletti RB, Dubinsky MC, Glickman JN, Gold BD, et al. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America. J Pediatr Gastroenterol Nutr 2007; 44: 653–74.

[8] Celikbilek M, Dogan S, Ozbakır O, Zararsız G, Kücük H, Gürsoy S, et al. Neutrophil-lymphocyte ratio as a predictor of disease severity in ulcerative colitis. J Clin Lab Anal 2013; 27: 72–6.

[9] Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19 Suppl A:5A-36A.

[10] Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study. N Engl J Med 1987; 317:1625-1629.

[11] Dave M, Loftus EV Jr. Mucosal healing in inflammatory bowel disease-a true paradigm of success? Gastroenterol Hepatol (N Y) 2012; 8:29-38.

[12] Park JJ, Yang SK, Ye BD, et al. Second Korean guidelines for the management of Crohn's disease. Intest Res 2017; 15:38-67.

[13] Choi CH, Moon W, Kim YS, et al. Second Korean guidelines for the management of ulcerative colitis. Intest Res 2017; 15:7-37.

[14] Mukewar S, Costedio M, Wu X, et al. Severe adverse outcomes of endoscopic perforations in patients with and without IBD.Inflamm Bowel Dis2014; 20:2056-2066.

[15] Magro F, Gionchetti P, Eliakim R, et al. Third European evidence based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis 2017; 11:649-670.

[16] Gomollón F, Dignass A, Annese V, et al. 3rd European evidence based consensus on the diagnosis and management of Crohn's disease 2016. Part 1: diagnosis and medical management. J Crohns Colitis 2017; 11:3-25.

[17] Demir AK, Demirtas A, Kaya SU, et al. The relationship between the neutrophil-lymphocyte ratio and disease activity in patients with ulcerative colitis. Kaohsiung J Med Sci 2015; 31: 585-590.

[18] Torun S, Tunc BD, Suvak B, et al. Assessment of neutrophillymphocyte ratio in ulcerative colitis: a promising marker in predicting disease severity. Clin Res Hepatol Gastroenterol 2012; 36:491-497.

[19] Gao SQ, Huang LD, Dai RJ, Chen DD, Hu WJ, Shan YF.Neutrophil-lymphocyte ratio: a controversial marker in predicting Crohn's disease severity. Int J Clin Exp Pathol 2015; 8:14779-14785.

[20] Celikbilek M, Dogan S, Ozbakır O, et al. Neutrophil-lymphocyte ratio as a predictor of disease

severity in ulcerative colitis. J Clin Lab Anal 2013; 27:72-76.

[21] Segal AW. How neutrophils kill microbes. Annu Rev Immunol 2005; 23:197-223.

[22] Collins CE, Rampton DS. Platelet dysfunction: a new dimension in inflammatory bowel disease. Gut 1995; 36:5-8.

[23] Kapsoritakis AN, Potamianos SP, Sfiridaki AI, et al. Elevated thrombopoietin serum levels in patients with inflammatory bowel disease. Am J Gastroenterol 2000; 95:3478-3481.

[24] Collins CE, Cahill MR, Newland AC, Rampton DS. Platelets circulate in an activated state in inflammatory bowel disease. Gastroenterology 1994; 106:840-845.

[25] Selby WS, Jewell DP. T lymphocyte subsets in inflammatory bowel disease: peripheral blood. Gut 1983; 24:99-105.

[26] Konikoff MR, Denson LA. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis 2006; 12:524-534.

[27] Erbayrak M, Turkay C, Eraslan E, Cetinkaya H, Kasapoglu B, Bektas M. The role of fecal calprotectin in investigating inflammatory bowel diseases. Clinics (Sao Paulo) 2009; 64:421-425.

[28] Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 2008; 103:162-169.

[29] Sutherland AD, Gearry RB, Frizelle FA. Review of fecal biomarkers in inflammatory bowel disease. Dis Colon Rectum 2008; 51:1283-1291